Viatris share price today

Name: Viatris Share Price Today (NASDAQ: VTRS) - Viatris Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

(VTRS)

Viatris share price is $11.33 & ₹981.09 as on 22 Jan 2025, 2.30 'hrs' IST

$11.33

▲

0.03

(0.27%)

Market is closed - opens 8 PM, 22 Jan 2025

View live Viatris share price in Dollar and Rupees. Guide to invest in Viatris stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Viatris, along with analyst recommendations, forecasts, and comprehensive financials.

Viatris share price movements

Today's Low: $11.28
Today's High: $11.43
$11.33
0.49%
Downside
Day's Volatility :1.31%
Upside
0.83%
52 Weeks Low: $9.93
52 Weeks High: $13.62
$11.33
12.4%
Downside
52 Weeks Volatility :27.12%
Upside
16.8%

Viatris Returns

Period	Viatris Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-2.16%	-7.4%	0.0%
6 Months	-3.42%	-5.2%	0.0%
1 Year	-3.99%	0.5%	0.0%
3 Years	-21.31%	8.3%	-11.0%

Viatris Key Statistics

in dollars & INR

Previous Close	$11.3
Open	$11.3
Today's High	$11.425
Today's Low	$11.275
Market Capitalization	$13.5B
Today's Volume	$7.6M
52 Week High	$13.6175
52 Week Low	$9.925
Revenue TTM	$15.0B
EBITDA	$4.6B
Earnings Per Share (EPS)	$-0.73
Dividend Yield	4.25%
Profit Margin	-5.87%
Quarterly Earnings Growth YOY	-0.71%
Return On Equity TTM	-4.34%

How to invest in Viatris from India?

It is very easy for Indian residents to invest directly in Viatris from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Viatris stock in both Indian Rupees (INR) and US Dollars (USD). Search for Viatris or VTRS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Viatris or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Viatris shares which would translate to 0.076 fractional shares of Viatris as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Viatris, in just a few clicks!

Returns in Viatris for Indian investors in Rupees

Investment Value

₹1,00,000

Viatris investment value today

Current value as on today

₹1,00,424

Returns

₹424

(+0.42%)

Returns from Viatris Stock

₹3,738 (-3.74%)

Dollar Returns

₹4,162 (+4.16%)

Indian investors sentiment towards Viatris

-41%

Period: Oct 23, 2024 to Jan 21, 2025. Change in 30 Days versus previous period

Search volume for Viatris on INDmoney from India has reduced in the last 30 days as on Jan 22, 2025. -41% less investors are searching Viatris in the last 30 days versus the previous period.

Indian Mutual Funds that invest in Viatris

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential Value Discovery Fund Direct Plan Growth	5015365	682691.48	1.11%
Motilal Oswal S&P 500 Index Fund Direct Growth	10297	17.61	0.03%

Global Institutional Holdings in Viatris

Vanguard Group Inc
11.82%
BlackRock Inc
7.88%
State Street Corp
5.29%
Davis Selected Advisers
5.25%
T. Rowe Price Associates, Inc.
4.09%
Amvescap Plc.
2.56%

Analyst Recommendation on Viatris

Hold

7%Buy

57%Hold

35%Sell

Based on 14 Wall street analysts offering stock ratings for Viatris(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Viatris

What analysts predicted

Upside of 18.71%

Target:

$13.45

Current:

$11.33

Insights on Viatris

Price Movement
In the last 7 days, VTRS stock has moved down by -3.6%
Decreasing Revenue
Revenue is down for the last 2 quarters, 3.79B → 3.73B (in $), with an average decrease of 1.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -326.4M → 94.8M (in $), with an average increase of 444.3% per quarter
VTRS vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 92.8% return, outperforming this stock by 93.7%
VTRS vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 195.8% return, outperforming this stock by 218.0%
Price to Sales
ForVTRS every $1 of sales, investors are willing to pay $0.9, whereas for Intra-cellular Therapies, Inc., the investors are paying $20.7 for every $1 of sales.

Viatris Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$11.4B	↓ 3.98%
Net Income	$352.5M	↓ 49.35%
Net Profit Margin	3.08%	↓ 2.76%

	FY19	Y/Y Change
Revenue	$11.5B	↑ 0.58%
Net Income	$16.8M	↓ 95.23%
Net Profit Margin	0.15%	↓ 2.93%

	FY20	Y/Y Change
Revenue	$11.9B	↑ 3.87%
Net Income	$-669.9M	↓ 4087.5%
Net Profit Margin	-5.61%	↓ 5.76%

	FY21	Y/Y Change
Revenue	$17.9B	↑ 49.73%
Net Income	$-1.3B	↑ 89.45%
Net Profit Margin	-7.1%	↓ 1.49%

	FY22	Y/Y Change
Revenue	$16.3B	↓ 9.08%
Net Income	$2.1B	↓ 263.79%
Net Profit Margin	12.78%	↑ 19.88%

	FY23	Y/Y Change
Revenue	$15.4B	↓ 5.14%
Net Income	$54.7M	↓ 97.37%
Net Profit Margin	0.35%	↓ 12.43%

	Q2 FY23	Q/Q Change
Revenue	$3.9B	↑ 5.08%
Net Income	$264.0M	↑ 17.49%
Net Profit Margin	6.74%	↑ 0.71%

	Q3 FY23	Q/Q Change
Revenue	$3.9B	↑ 0.59%
Net Income	$331.6M	↑ 25.61%
Net Profit Margin	8.41%	↑ 1.67%

	Q4 FY23	Q/Q Change
Revenue	$3.8B	↓ 2.98%
Net Income	$-765.6M	↓ 330.88%
Net Profit Margin	-20.02%	↓ 28.43%

	Q1 FY24	Q/Q Change
Revenue	$3.7B	↓ 4.21%
Net Income	$113.9M	↓ 114.88%
Net Profit Margin	3.11%	↑ 23.13%

	Q2 FY24	Q/Q Change
Revenue	$3.8B	↑ 3.64%
Net Income	$-326.4M	↓ 386.57%
Net Profit Margin	-8.6%	↓ 11.71%

	Q3 FY24	Q/Q Change
Revenue	$3.7B	↓ 1.54%
Net Income	$94.8M	↓ 129.04%
Net Profit Margin	2.54%	↑ 11.14%

	FY18	Y/Y Change
Profit	$4.0B	↓ 16.34%

	FY19	Y/Y Change
Profit	$3.9B	↓ 2.6%

	FY20	Y/Y Change
Profit	$3.8B	↓ 2.59%

	FY21	Y/Y Change
Profit	$5.6B	↑ 46.85%

	FY22	Y/Y Change
Profit	$6.5B	↑ 16.53%

	FY23	Y/Y Change
Profit	$6.4B	↓ 0.9%

	Q2 FY23	Q/Q Change
Profit	$1.6B	↑ 4.31%

	Q3 FY23	Q/Q Change
Profit	$1.7B	↑ 5.14%

	Q4 FY23	Q/Q Change
Profit	$1.6B	↓ 4.77%

	Q1 FY24	Q/Q Change
Profit	$1.5B	↓ 6.62%

	Q2 FY24	Q/Q Change
Profit	$1.5B	↓ 0.72%

	Q3 FY24	Q/Q Change
Profit	$1.5B	↓ 2.27%

	FY18	Y/Y Change
Operating Cash Flow	$2.3B	↑ 13.41%
Investing Cash Flow	$-1.2B	↑ 23.97%
Financing Cash Flow	$-1.1B	↓ 42.37%

	FY19	Y/Y Change
Operating Cash Flow	$1.8B	↓ 22.97%
Investing Cash Flow	$-525.4M	↓ 56.59%
Financing Cash Flow	$-1.2B	↑ 7.16%

	FY20	Y/Y Change
Operating Cash Flow	$1.2B	↓ 31.71%
Investing Cash Flow	$-301.1M	↓ 42.69%
Financing Cash Flow	$-605.7M	↓ 48.19%

	FY21	Y/Y Change
Operating Cash Flow	$3.0B	↑ 144.92%
Investing Cash Flow	$-117.8M	↓ 60.88%
Financing Cash Flow	$-3.0B	↑ 397.28%

	FY22	Y/Y Change
Operating Cash Flow	$3.0B	↓ 2.13%
Investing Cash Flow	$1.5B	↓ 1390.75%
Financing Cash Flow	$-3.9B	↑ 28.75%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$514.9M	↓ 46.98%
Investing Cash Flow	$-76.6M	↓ 89.78%
Financing Cash Flow	$-303.5M	↓ 68.86%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$834.1M	↑ 61.99%
Investing Cash Flow	$-53.8M	↓ 29.77%
Financing Cash Flow	$-97.6M	↓ 67.84%

Viatris Technicals Summary

Sell

Neutral

Buy

Viatris is currently in a neutral trading position according to technical analysis indicators.

Viatris Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Viatris Inc.	-9.53%	-3.42%	-3.99%	-21.31%	-30.84%
Intra-cellular Therapies, Inc.	50.24%	63.32%	89.89%	184.62%	434.52%
Haleon Plc Spon Ads	-4.94%	3.01%	11.46%	24.7%	24.7%
Zoetis Inc.	0.98%	-7.66%	-11.81%	-17.08%	21.7%
Neurocrine Biosciences Inc.	4.58%	-1.8%	2.03%	88.85%	44.46%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.7	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	28.88	28.88	1.66	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	31.12	31.12	2.58	5.88	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	38.2	38.2	0.33	6.6	0.16	0.12	NA	26.87

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Viatris Inc.	Hold	$13.5B	-30.84%	224.4	-5.87%
Intra-cellular Therapies, Inc.	Buy	$13.4B	434.52%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$41.8B	24.7%	28.88	10.75%
Zoetis Inc.	Buy	$74.8B	21.7%	31.12	26.55%
Neurocrine Biosciences Inc.	Buy	$14.5B	44.46%	38.2	17.21%

Viatris Dividend announcements

Viatris Dividends December, 2024
In the quarter ending December,2024. Viatris has declared dividend of $0.12
Read More

About Viatris

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Organization	Viatris
Employees	32000
CEO	Mr. Scott Andrew Smith Ph.D.
Industry	Health Technology

Management People of Viatris

Name	Title
Mr. Scott Andrew Smith Ph.D.	CEO & Director
Mr. Brian S. Roman	Chief Legal Officer
Ms. Theodora Mistras	Chief Financial Officer
Mr. Paul B. Campbell	Chief Accounting Officer, Senior VP & Corporate Controller
Mr. Ramkumar V. Rayapureddy	Chief Information Officer
Mr. Andrew Enrietti	Chief People Officer
Mr. Menassie Taddese M.B.A.	President of Emerging Markets
Mr. Derek Glover	Chief Quality Officer
Ms. Lara Ramsburg	Chief Corporate Affairs Officer
Dr. Jeffrey Nau MMS, Ph.D.	President of Viatris Eye Care Division

Important FAQs about investing in Viatris from India :

What is Viatris share price today?

Viatris share price today stands at $11.33, Open: $11.30 ; Previous Close: $11.30 ; High: $11.43 ; Low: $11.28 ; 52 Week High: $13.62 ; 52 Week Low: $9.93. The stock opens at $11.30, after a previous close of $11.30. The stock reached a daily high of $11.43 and a low of $11.28, with a 52-week high of $13.62 and a 52-week low of $9.93.

Can Indians buy Viatris shares?

Yes, Indians can invest in the Viatris (VTRS) from India.

With INDmoney, you can buy Viatris at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Viatris at zero transaction cost.

How can I buy Viatris shares from India?

It is very easy to buy Viatris from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Viatris be purchased?

Yes, you can buy fractional shares of Viatris with INDmoney app.

What are the documents required to start investing in Viatris stocks?

To start investing in Viatris, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.